Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | GLA | P06280 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | HTR2A | P28223 | 10/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | HTR2C | P28335 | 1/20 | 0.51 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | PPARA | Q07869 | 2/20 | 0.47 |
| ▸ | PPARD | Q03181 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4109056 | 0.88 | KDM4E (0.71) | KDM4EALDH1A1GLATDP1MEN1 | |
| SCHEMBL4575242 | 0.80 | TMEM97 (0.46) | KDM4ETDP1MEN1KMT2ATMEM97 | |
| SCHEMBL3903635 | 0.79 | CA2 (0.49) | KDM4EALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4575193 | 0.79 | KDM4E (0.45) | KDM4ETDP1HTR2AMEN1KMT2A | |
| SCHEMBL3945922 | 0.76 | KDM4E (0.68) | KDM4EALDH1A1GLATDP1MEN1 | |
| SCHEMBL14731899 | 0.75 | TMEM97 (0.68) | KDM4EGLATDP1TMEM97PPARA | |
| SCHEMBL13359867 | 0.74 | POLB (0.72) | KDM4EALDH1A1HTR2AMEN1KMT2A | |
| SCHEMBL4104332 | 0.74 | KDM4E (0.61) | KDM4EALDH1A1GLATDP1MEN1 | |
| SCHEMBL29885821 | 0.74 | CYP3A4 (0.48) | ALDH1A1HTR2AMEN1KMT2A | |
| SCHEMBL1094342 | 0.74 | CYP3A4 (0.48) | ALDH1A1HTR2AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7319104-B2 | hPPARs activators | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-15 | — | — | US | disclosed |
| US-20050137212-A1 | Hppars activators | SMITHKLINE BEECHAM CORPORATION | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137212-A1 | Hppars activators | PPARG, PPARA, PPARD | KDM4E 4112/4885ALDH1A1 645/4885GLA 343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.